Literature DB >> 10087106

Imaging pulmonary disease in AIDS: state of the art.

J E Kuhlman1.   

Abstract

The spectrum of pulmonary diseases in AIDS including infections and neoplasms that affect the lungs are reviewed. Characteristic plain film and CT findings are illustrated.

Entities:  

Mesh：

Year:  1999        PMID： 10087106     DOI： 10.1007/s003300050682

Source DB:  PubMed          Journal:  Eur Radiol        ISSN： 0938-7994            Impact factor:   5.315


  7 in total

1.  Risk Factors Associated With Quantitative Evidence of Lung Emphysema and Fibrosis in an HIV-Infected Cohort.

Authors:  Joseph K Leader; Kristina Crothers; Laurence Huang; Mark A King; Alison Morris; Bruce W Thompson; Sonia C Flores; Michael B Drummond; William N Rom; Philip T Diaz
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

2.  Pulmonary Kaposi sarcoma in AIDS.

Authors:  Sumedh S Hoskote; Vishal P Patel
Journal:  Mayo Clin Proc       Date:  2012-10       Impact factor: 7.616

3.  Pleural effusions in patients with AIDS.

Authors:  R F Miller; S J Howling; A J Reid; P J Shaw
Journal:  Sex Transm Infect       Date:  2000-04       Impact factor: 3.519

4.  Progressive intrathoracic lymphadenopathy: EBV associated non-Hodgkin's lymphoma.

Authors:  R F Miller; E L Jones; M J Duddy; M Shahmanesh
Journal:  Sex Transm Infect       Date:  2002-02       Impact factor: 3.519

Review 5.  Imaging techniques for Kaposi's sarcoma.

Authors:  D O'Mahony; Ah Gandjbakche; M Hassan; A Vogel; R Yarchoan
Journal:  J HIV Ther       Date:  2008-09

6.  Pneumocystis Pneumonia Mimicking Atypical Pneumonia in a Patient With Human Immunodeficiency Virus Infection.

Authors:  Takehiro Hashimoto; Masaru Ando; Shinichi Nureki; Kosaku Komiya; Kazufumi Hiramatsu
Journal:  Cureus       Date:  2022-08-25

7.  Kaposi's sarcoma: a reversible cause of ARDS in HIV-infected patient.

Authors:  Xavier Repessé; Siu-Ming Au; Cyril Charron; Antoine Vieillard-Baron
Journal:  Intensive Care Med       Date:  2013-03-20       Impact factor: 17.440
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.